Bull Case

Canadian adult-use and medical demand stabilizes while retail expansion and product mix improve, lifting revenue and margins versus smaller Canadian peers with weaker scale.

International medical and export channels scale faster, diversifying sales and reducing reliance on low-margin domestic flower compared with peers concentrated in Canada.

Cost actions and manufacturing rationalization narrow operating losses, improving operating leverage more quickly than peers still carrying heavier fixed-cost structures.

Balance-sheet pressure eases through better cash generation and refinancing, lowering financing drag relative to peers with similarly negative interest coverage.

Base Case

Domestic demand remains uneven and pricing stays competitive, keeping revenue growth modest and margins below profitable peers with stronger brand and distribution reach.

Product mix and efficiency gains offset only part of the loss burden, so operating margins stay negative but improve from TTM levels.

International and medical contributions grow gradually, but they remain too small to fully re-rate ACB versus larger, more diversified cannabis peers.

Leverage stays manageable but still constrains flexibility, leaving financing costs a persistent headwind relative to peers with stronger coverage.

Bear Case

Canadian pricing pressure and weak volume trends compress revenue and gross profit, worsening losses versus peers with better cost control.

Operating losses persist and cash burn remains elevated, limiting reinvestment and forcing further dilution or expensive financing.

International growth underdelivers, leaving ACB more exposed to the mature Canadian market than peers with stronger export or U.S.-adjacent optionality.

High leverage and negative interest coverage amplify downside, making refinancing risk and covenant pressure more severe than for less levered peers.

Overall Score

ACB’s forward path is most likely a slow operational recovery with limited profitability, while upside depends on faster margin repair and downside remains tied to leverage and Canadian pricing pressure.